ストックスクリーナーアプリを入手
4.88
5.24%
-0.27
前日終値:
$5.15
開ける：
$5.09
24時間の取引高:
322.47K
Relative Volume:
1.45
時価総額：
$209.27M
収益：
-
当期純損益:
$-19.90M
株価収益率:
-9.2075
EPS:
-0.53
ネットキャッシュフロー:
$-19.80M
1週間 パフォーマンス:
+24.17%
1か月 パフォーマンス:
+30.83%
6か月 パフォーマンス:
-22.54%
1年 パフォーマンス:
+33.70%
1日の値動き範囲:
$4.88
$5.16
1週間の範囲:
$3.88
$5.25
52週間の値動き範囲:
$3.19
$6.8184
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
名前
Diamedica Therapeutics Inc
セクター
電話
(763) 496-5454
住所
301 CARLSON PARKWAY, MINNEAPOLIS, MN
DMAC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
4.88 | 197.26M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-24 | 再開されました | Craig Hallum | Buy |
| 2023-06-22 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-04-09 | 開始されました | Oppenheimer | Outperform |
| 2021-02-17 | 開始されました | ROTH Capital | Buy |
| 2020-10-30 | 開始されました | Guggenheim | Buy |
| 2020-07-08 | 開始されました | Maxim Group | Buy |
| 2019-04-30 | 開始されました | Dougherty & Company | Buy |
| 2019-03-05 | 開始されました | Lake Street | Buy |
すべてを表示
Diamedica Therapeutics Inc (DMAC) 最新ニュース
DiaMedica Therapeutics Inc. Stock Analysis and ForecastFree Market Volatility Navigation Tips - PrintWeekIndia
Is DiaMedica Therapeutics Inc. stock overhyped or has real potentialBreakthrough financial growth - jammulinksnews.com
DiaMedica raises $30.1M in private placement for preeclampsia, stroke treatment - The Business Journals
The Beat: Entrust names new CEO, DiaMedica raises millions - The Business Journals
DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement - BioSpace
DiaMedica Therapeutics Secures $30.1 Million in Private Placement - TipRanks
DiaMedica Therapeutics closes $30.1 million private placement - Investing.com India
Is DiaMedica Therapeutics Inc. a good long term investmentDynamic profit expansion - jammulinksnews.com
What drives DiaMedica Therapeutics Inc. stock priceExtraordinary market timing - jammulinksnews.com
What analysts say about DiaMedica Therapeutics Inc. stockFree Stock Market Knowledge Sharing - jammulinksnews.com
Diamedica Therapeutics shares rise 11.01% intraday after $30.1M private placement and positive trial results for DM199 in preeclampsia. - AInvest
DiaMedica Announces $30.1M Private Placement for DM199 - TipRanks
DiaMedica secures $30.1 million in private placement for clinical trials By Investing.com - Investing.com South Africa
DiaMedica secures $30.1 million in private placement for clinical trials - Investing.com
DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline - Business Wire
DiaMedica Therapeutics (NASDAQ:DMAC) Price Target Raised to $12.00 - Defense World
DiaMedica shares drop 35% following InvestingPro’s overvalued warning By Investing.com - Investing.com India
DiaMedica gains on positive mid-stage trial data for lead drug in preeclampsia - MSN
What makes DiaMedica Therapeutics Inc. stock price move sharplyReliable High Profit Alerts - beatles.ru
DiaMedica stock price target raised to $12 from $10 at H.C. Wainwright - Investing.com
DiaMedica Therapeutics to be included in the Russell 2000 and 3000 indexes - MSN
DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer - BioSpace
DiaMedica Therapeutics reports interim results from DM199 study - TipRanks
DiaMedica Announces Positive Interim Results for DM199 Study - TipRanks
DiaMedica reports positive interim results for preeclampsia treatment - Investing.com
Why DiaMedica Therapeutics Inc. stock attracts strong analyst attentionVerified Return Tips - Newser
How DiaMedica Therapeutics Inc. stock performs during market volatilityValue Pick Scanner - Newser
3 Promising Penny Stocks With Market Caps Under $200M - simplywall.st
Trend Tracker for (DMAC) - news.stocktradersdaily.com
DiaMedica Therapeutics Inc.(NasdaqCM: DMAC) added to Russell 2000 Dynamic Index - MarketScreener
DiaMedica Therapeutics Inc.(NasdaqCM: DMAC) added to Russell 3000 Growth Index - MarketScreener
DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes - Business Wire
DiaMedica Therapeutics Insiders Up US$4.1m On US$9.00m Investment - simplywall.st
Millennium Management LLC Increases Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
42,212 Shares in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Purchased by Jane Street Group LLC - Defense World
Can DiaMedica Deliver A Breakthrough In Preeclampsia Treatment? - RTTNews
Diamedica Therapeutics Inc (DMAC) 財務データ
収益
当期純利益
現金流量
EPS
3.32%
1.57%
大文字化:
|
ボリューム (24 時間):